Cargando…

Omalizumab in children with severe allergic disease: a case series

BACKGROUND: Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crisafulli, Giuseppe, Caminiti, Lucia, Chiera, Fernanda, Arasi, Stefania, Salzano, Giuseppina, Panasiti, Ilenia, Barbalace, Andrea, Pajno, Giovanni Battista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332555/ https://www.ncbi.nlm.nih.gov/pubmed/30642367 http://dx.doi.org/10.1186/s13052-019-0602-5

Ejemplares similares

The safety of oral immunotherapy for food allergy during maintenance phase: Effect of counselling on adverse reactions
por: Arasi, Stefania, et al.
Publicado: (2019)

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis
por: Arasi, Stefania, et al.
Publicado: (2016)

Allergen immunotherapy
por: Crisafulli, Giuseppe, et al.
Publicado: (2014)

Long term treatment with omalizumab in adolescent with refractory solar urticaria
por: Iannelli, Mauro, et al.
Publicado: (2021)

Food protein induced enterocolitis syndrome caused by rice beverage
por: Caminiti, Lucia, et al.
Publicado: (2013)

Oral immunotherapy in clinical practice
por: Arasi, Stefania, et al.
Publicado: (2015)

Thyrotropin serum levels and coexistence with Hashimoto’s thyroiditis as predictors of malignancy in children with thyroid nodules
por: Zirilli, Giuseppina, et al.
Publicado: (2019)

The future outlook on allergen immunotherapy in children: 2018 and beyond
por: Arasi, Stefania, et al.
Publicado: (2018)

Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
por: Passanisi, Stefano, et al.
Publicado: (2022)

Are Children Most of the Submerged Part of SARS-CoV-2 Iceberg?
por: Passanisi, Stefano, et al.
Publicado: (2020)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Vulvar contact dermatitis caused by sensitization to colophonium in a patient with type 1 diabetes
por: Salzano, Giuseppina, et al.
Publicado: (2021)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Sex, Allergic Diseases and Omalizumab
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap
por: Ricciardi, Luisa, et al.
Publicado: (2022)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life
por: Galletta, Francesca, et al.
Publicado: (2023)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Subclinical Hypothyroidism in Children: When a Replacement Hormonal Treatment Might Be Advisable
por: Crisafulli, Giuseppe, et al.
Publicado: (2019)

Maturity Onset Diabetes of the Young is Not Necessarily Associated with Autosomal Inheritance: Case Description of a De Novo HFN1A Mutation
por: Salzano, Giuseppina, et al.
Publicado: (2019)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Effective omalizumab treatment influenced eosinophil function in severe allergic asthmatics
por: Yan, Huacheng, et al.
Publicado: (2023)

Phenotypic Expression of Autoimmunity in Children With Autoimmune Thyroid Disorders
por: Aversa, Tommaso, et al.
Publicado: (2019)

Nutrition and Avoidance Diets in Children With Food Allergy
por: Corica, Domenico, et al.
Publicado: (2020)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Long-term benefits of omalizumab in a patient with severe non-allergic asthma
por: Menzella, Francesco, et al.
Publicado: (2011)

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

Impact of the Allergic Therapeutic Adherence in Children with Allergic Rhinitis and ADHD: A Pilot Study
por: Gambadauro, Antonella, et al.
Publicado: (2023)

Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
por: Sztafińska, Anna, et al.
Publicado: (2021)

Alpha-Gal Syndrome in Children: Peculiarities of a “Tick-Borne” Allergic Disease
por: Saretta, Francesca, et al.
Publicado: (2021)

Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
por: Just, Jocelyne, et al.
Publicado: (2021)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Novel treatment of allergic fungal sinusitis using omalizumab
por: Evans, Martin Oman, et al.
Publicado: (2014)

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
por: Ashkenazi, Moshe, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_abm9ei017q85vpbv9rcm85hrkr